BioCentury
ARTICLE | Clinical News

RI-002 regulatory update

August 8, 2016 7:00 AM UTC

FDA issued a complete response letter to a BLA from ADMA for R1-002, an IV immunoglobulin (IVIG), to treat primary immunodeficiency disease (PIDD). According to ADMA, the agency cited no safety or eff...